// App-Quantinova.ai

AB0311 : THE PROPER STUDY: RESULTS OF THE FIRST INTERIM ANALYSIS OF A PAN-EU REAL-WORLD STUDY OF SB5 BIOSIMILAR FOLLOWING TRANSITION FROM REFERENCE ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS OR PSORIATIC ARTHRITIS

Researchers

Presenter

  • U. Mller-Ladner

Principal Investigators

  • K. Gaffney

  • D. Jadon

  • U. Freudensprung

  • J. Addison

Medical Centers

  • Kerckhoff Clinic, Bad Nauheim, Germany

  • Norfolk and Norwich University Hospitals NHS Trust, Norwich, United Kingdom.

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Shire International GmbH, Zug, Switzerland

  • Biogen Idec Ltd, Maidenhead, United Kingdom

Locations

  • Germany

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Axial spondyloarthritis

  • Rheumatoid arthritis

  • Psoriatic arthritis

  • Spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

Outcome

  • N/A

Study Design

  • Observational

Phase

  • I

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved